RESUMEN
BACKGROUND: Only clinically validated HPV assays can be accepted in cervical cancer screening. OBJECTIVES: To update the list of high-risk HPV assays that fulfil the 2009 international validation criteria (Meijer-2009). DATA SOURCES: PubMed/Medline, Embase, Scopus, references from selected studies; published in January 2014 to August 2020. STUDY ELIGIBILITY CRITERIA: HPV test validation studies and primary screening studies, involving testing with an index HPV test and a comparator HPV test with reporting of disease outcome (occurrence of histologically confirmed cervical precancer; CIN2+). PARTICIPANTS: Women participating in cervical cancer screening. INTERVENTIONS: Testing with an index and a comparator HPV test of clinician-collected cervical specimens and assessment of disease outcome (Asunto(s)
Alphapapillomavirus
, Detección Precoz del Cáncer
, Papillomaviridae/aislamiento & purificación
, Infecciones por Papillomavirus
, Neoplasias del Cuello Uterino
, Femenino
, Técnicas de Genotipaje
, Humanos
, Infecciones por Papillomavirus/diagnóstico
, Reproducibilidad de los Resultados
, Sensibilidad y Especificidad
, Neoplasias del Cuello Uterino/diagnóstico
, Neoplasias del Cuello Uterino/virología